Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

1

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality, with only 15-20% of patients having resectable tumors at diagnosis.
2

Neoadjuvant chemotherapy (NAC) may improve resectability and survival in patients with borderline resectable and locally advanced pancreatic cancer.
3

This study evaluates survival outcomes of patients undergoing radical surgery with vascular resection after NAC compared to those with upfront surgery.
4

Key predictive factors for overall survival and progression-free survival were analyzed to identify patients who benefit most from NAC.
5

The study utilized a retrospective cohort design, collecting data from a single medical center over a ten-year period to assess treatment efficacy.

Updates In Surgery

by Ting-Kai Liao, Wei-Hsun Lu, Ping-Jui Su, Chih-Jung Wang, Ying Jui Chao, Yan-Shen Shan
May 28, 2026

1